Search: onr:"swepub:oai:DiVA.org:uu-241399" >
Renal function thre...
-
Mjörnstedt, Lars,1956Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery
(author)
Renal function three years after early conversion from a calcineurin inhibitor to everolimus : results from a randomized trial in kidney transplantation
- Article/chapterEnglish2015
Publisher, publication year, extent ...
-
2014-09-30
-
Frontiers Media SA,2015
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-241399
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-241399URI
-
https://doi.org/10.1111/tri.12437DOI
-
https://gup.ub.gu.se/publication/205037URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
In a 36-month, open-label, multicenter trial, 202 kidney transplant recipients were randomized at week 7 post-transplant to convert to everolimus or remain on cyclosporine: 182 were analyzed to month 36 (92 everolimus, 90 controls). Mean (SD) change in measured GFR (mGFR) from randomization to month 36 was 1.3 (14.0)ml/min with everolimus versus -1.7 (15.4)ml/min in controls (P=0.210). In patients who remained on treatment, mean mGFR improved from randomization to month 36 by 7.9 (11.5)ml/min with everolimus (n=37) but decreased by 1.4 (14.7)ml/min in controls (n=62) (P=0.001). During months 12-36, death-censored graft survival was 100%, patient survival was 98.9% and 96.7% in the everolimus and control groups, respectively, and 13.0% and 11.1% of everolimus and control patients, respectively, experienced mild biopsy-proven acute rejection (BPAR). Protocol biopsies in a limited number of on-treatment patients showed similar interstitial fibrosis progression. Donor-specific antibodies were present at month 36 in 6.3% (2/32) and 18.0% (9/50) of on-treatment everolimus and control patients with available data (P=0.281). During months 12-36, adverse events were comparable, but discontinuation was more frequent with everolimus (33.7% vs. 10.0%). Conversion from cyclosporine to everolimus at 7weeks post-transplant was associated with a significant benefit in renal function at 3years when everolimus was continued.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Sorensen, Soren Schwartz
(author)
-
von zur Mühlen, BengtUppsala universitet,Transplantationskirurgi(Swepub:uu)bengmuhl
(author)
-
Jespersen, Bente
(author)
-
Hansen, Jesper M.
(author)
-
Bistrup, Claus
(author)
-
Andersson, Helene
(author)
-
Gustafsson, Bengt I.,1955Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery(Swepub:gu)xgusbe
(author)
-
Solbu, Dag
(author)
-
Holdaas, Hallvard
(author)
-
Göteborgs universitetInstitutionen för kliniska vetenskaper, Avdelningen för kirurgi
(creator_code:org_t)
Related titles
-
In:Transplant International: Frontiers Media SA28:1, s. 42-510934-08741432-2277
Internet link
Find in a library
To the university's database
- By the author/editor
-
Mjörnstedt, Lars ...
-
Sorensen, Soren ...
-
von zur Mühlen, ...
-
Jespersen, Bente
-
Hansen, Jesper M ...
-
Bistrup, Claus
-
show more...
-
Andersson, Helen ...
-
Gustafsson, Beng ...
-
Solbu, Dag
-
Holdaas, Hallvar ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Surgery
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Urology and Neph ...
- Articles in the publication
-
Transplant Inter ...
- By the university
-
Uppsala University
-
University of Gothenburg